| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi |
| Completed | 3 | 400 | Europe | Fluticasone propionate/formoterol fumarate | SkyePharma AG | Asthma | 07/07 | 07/07 | | |
| Completed | 3 | 228 | Europe | FLUTIFORM® (Formoterol fumarate / Fluticasone propionate) | Mundipharma Research Limited | Asthma Bronchiale | 01/08 | 01/08 | | |
NCT00394199: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma |
|
|
| Completed | 3 | 357 | US, Canada | Fluticasone propionate/Formoterol Fumarate 100/10, Flutiform 100/10, Fluticasone propionate 100, Fluticasone 100, Formoterol fumarate 10, SKP Formoterol 10 | SkyePharma AG | Asthma | 02/08 | 02/08 | | |
| Completed | 3 | 211 | Europe, RoW | FLUTIFORM® (Formoterol fumarate / Fluticasone propionate) | Mundipharma Research Limited | Asthma | 02/08 | 02/08 | | |
NCT00393952: New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma |
|
|
| Completed | 3 | 557 | US | Fluticasone propionate/Formoterol fumarate 250/10, FlutiForm 250/10, Placebo, SKP Placebo, Fluticasone propionate/Formoterol fumarate 100/10, FlutiForm 100/10, Fluticasone propionate 250, Fluticasone 250, Formoterol fumarate 10, SKP Formoterol 10 | SkyePharma AG | Asthma | 04/08 | 04/08 | | |
NCT00393991: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma |
|
|
| Completed | 3 | 475 | US, Canada | Fluticasone propionate/formoterol fumarate 100/10, Flutiform 100/10, Fluticasone propionate 100, SKP Fluticasone 100, Formoterol fumarate 10, SKP Formoterol 10, Placebo, SKP Placebo | SkyePharma AG | Asthma | 04/08 | 04/08 | | |
NCT00563056 / 2007-001634-13: An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma |
|
|
| Completed | 3 | 227 | Europe | Flutiform, Flixotide plus Foradil | Mundipharma Research Limited | Asthma Bronchiale | 04/08 | 04/08 | | |
NCT00649025 / 2007-005653-37: A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults |
|
|
| Completed | 3 | 438 | US, Europe, RoW | FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA, Flovent | SkyePharma AG, Abbott, MDS Pharma Services | Asthma | 10/08 | 10/08 | | |
| Completed | 3 | 1667 | Europe | Flutiform 250/10 micrograms, Flutiform 50/5 micrograms, Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms, Flixotide pMDI 250 micrograms | Mundipharma Research Limited | Asthma, Bronchial | 06/09 | 10/09 | | |
NCT01099722 / 2009-017223-25: Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma |
|
|
| Completed | 3 | 261 | Europe, RoW | Flutiform, Symbicort Turbohaler | Mundipharma Research Limited | Asthma | 11/10 | 07/11 | | |
| Completed | 3 | 498 | Europe, RoW | Flutiform, Seretide, Flixotide | Mundipharma Research Limited | Asthma | 09/13 | 11/13 | | |
| Completed | 3 | 1767 | Europe, RoW | Flutiform, Formoterol | Mundipharma Research Limited | Chronic Obstructive Pulmonary Disease | 04/16 | 05/16 | | |
NCT02195375: Flutiform® Compared With Seretide® in the Treatment of COPD |
|
|
| Completed | 2/3 | 923 | RoW | Flutiform 500/20 µg BID, Flutiform 250/10 µg BID, Seretide Accuhaler 50/500 µg BID | Mundipharma Research Limited | Chronic Obstructive Pulmonary Disease | 05/16 | 05/16 | | |
